South Korea Autoinjectors Market Overview

The South Korea Autoinjectors Market was valued at USD 332.88 Million in 2025 and is projected to reach USD 1,257.25 Million by 2035, growing at a CAGR of 14.21%, up from USD 202.29 Million in 2020. South Korea is the third-largest country in the Asia-Pacific Autoinjectors Market report with an 11.8% regional share, behind China and Japan, and grows above the regional 14.12% — a rate that, unusually for a developed market, is driven as much by what Korea makes as by what it consumes.

The Global Autoinjectors Market report places South Korea's significance on the biosimilar supply side. Celltrion — whose Yuflyma interchangeability designation the FDA expanded on 23 May 2025 to include the 40 mg and 80 mg autoinjector presentations — anchors a domestic biosimilar industry in which every launch requires its own device presentation, and Samsung Bioepis commercialises Hadlima, Pyzchiva and a broad immunology, oncology and ophthalmology portfolio from the same Songdo, Incheon cluster. The country also negotiated the 15% U.S. tariff tier under Section 232, protecting its export position relative to the 100% default. The Ministry of Food and Drug Safety (MFDS) regulates combination products, and this report quantifies the market across twelve segmentation axes and 27 segment tables with a dedicated four-region analysis.

What Shapes the Korean Market

1. Biosimilars as the growth engine. Interchangeability is now granted at device-presentation level: the FDA's expansion of Celltrion's Yuflyma designation to the 40 mg and 80 mg autoinjectors — following U.S. availability of the 80 mg dose in January 2024 — means a Korean biosimilar competes on device experience as much as on price, in the U.S., Europe and at home. Celltrion's Songdo facilities carry roughly 250,000 litres of monoclonal-antibody capacity across Remsima, Zymfentra, Yuflyma, Truxima, Herzuma, Vegzelma, Omlyclo, Steqeyma, Avtozma and other products; Samsung Bioepis adds Hadlima (adalimumab, prefilled syringe and autoinjector), Pyzchiva (ustekinumab), Byooviz and Epysqli. With 90 U.S. biosimilars now approved per the FDA Purple Book, each Korean launch is a new platform qualification.

2. Tariff position and export logic. The 15% Section 232 tier gives Korean-origin biologics and devices a structural advantage over higher-tier competitors in the U.S. market, and the report's investment scenario treats Korea as a beneficiary of the reshoring wave rather than a casualty. Because the same Songdo lines serve domestic and export presentations, one autoinjector qualification serves both — the report's central argument for Korea's above-regional growth.

3. Domestic demand: mature, ageing and digitally engaged. Korea combines a rapidly ageing population aligned with the WHO ageing driver, near-universal national health insurance covering biologics, and the region's most digitally engaged patient base — the conditions under which integrated connectivity (Asia-Pacific's fastest-growing connectivity configuration at 15.41% CAGR) and reusable platforms (15.26%) gain adoption early. Endocrinology, metabolic and hormonal disorders is the region's fastest-growing therapy area at 14.86% as GLP-1 access widens under NHIS reimbursement.

South Korea Autoinjectors Market by Region — In-Depth Analysis

South Korea's autoinjector market is unusually concentrated: the Seoul Capital Area holds about half the population, the country's dominant hospital cluster and — in Songdo, Incheon — the biosimilar manufacturing base that gives Korea its global role. The regional view reads each zone against the report's drivers.

How the regional analysis is used in the report. The four-region view maps Korea's revenue lines from the 27 segment tables onto hospital concentration, bio-cluster location, NHIS and MFDS decision-making and age structure, so that a device maker can see where Korean biosimilar presentations are qualified, a platform supplier where Songdo and Osong demand is densest, and a pharma partner where each modality's prescribing base sits. Quantified sub-national revenue splits (by region, by province, or by domestic/export channel) are available as a customization of this report — request the regional data cut here.

South Korea Segment Insights

Growth rates shown are the Asia-Pacific values from the report's regional segment tables; Korea's own trajectory (14.21%) runs slightly above them. Korea's mix is the most biosimilar- and antibody-weighted in Asia-Pacific — adalimumab, ustekinumab, infliximab and other high-concentration subcutaneous antibodies delivered by autoinjector — and the report identifies it, with Japan, as an early-adopter market for connectivity and reusable platforms.

Market Drivers and Restraints in South Korea

• Driver — biosimilar exports with device-level interchangeability. Celltrion's Yuflyma 40 mg / 80 mg autoinjector designation and Samsung Bioepis's Hadlima and Pyzchiva presentations make device qualification a core competitive variable.
• Driver — the 15% Section 232 tariff tier. A structural export advantage relative to the 100% default and higher country tiers.
• Driver — ageing and near-universal coverage. The WHO ageing driver combined with NHIS reimbursement of biologics and GLP-1s.
• Driver — global platform supply. Ypsomed, SHL Medical (Taiwan), Owen Mumford, Gerresheimer and Haselmeier serve Korean biosimilar makers and the multinational base; Fresenius Kabi competes in the imported-biosimilar segment.
• Restraint — NHIS price control. Reference-price listing and periodic cuts compress device economics, confining premium features to early adopters.
• Restraint — MFDS combination-product classification. Distinct pathways from other Asian regulators multiply qualification cost for a single presentation.
• Restraint — substitution and counterfeits. Oral GLP-1s and needle-free epinephrine are modelled as substitutes; counterfeit GLP-1 pens seized in the U.S. supply chain (FDA) raise the serialisation bar for exporters.

Competitive Landscape

South Korea's competitive structure is defined by its two biosimilar majors — Celltrion and Samsung Bioepis — which own the molecule and select the device, sourcing platforms from Ypsomed, SHL Medical, Owen Mumford, Gerresheimer, Haselmeier and Nemera. Multinational platform users Novo Nordisk, Eli Lilly, Sanofi, AbbVie, AstraZeneca and UCB serve branded demand, while Nipro, Terumo, SCHOTT Pharma, West Pharmaceutical Services and Datwyler anchor primary containers. The report profiles 151 companies across 15 chapters with company details, financials, product summary and recent developments.

Report Scope — South Korea

Key Questions Answered

• How large is the South Korea autoinjectors market and why does it grow above the Asia-Pacific average?
• How does device-presentation-level interchangeability (Yuflyma 40 mg / 80 mg) change the competitive value of an autoinjector for Korean biosimilar exporters?
• Which Korean regions carry the deepest demand, and where do the Songdo, Osong and Daegu clusters place manufacturing?
• How do the 15% Section 232 tariff tier and NHIS reference pricing shape Korea's domestic and export economics?
• Which global platform specialists and primary-container suppliers are best positioned to serve Celltrion, Samsung Bioepis and the multinational base?

This country report is drawn from the Global Autoinjectors Market report. Related coverage: Asia-Pacific Autoinjectors Market report, China, Japan, India, North America, United States, Canada, Mexico, Europe, Latin America and Middle East & Africa autoinjectors market reports.